Hims & Hers shares technical analysis: Breakout attempt at $29.24 resistance

Hims & Hers shares technical analysis: Breakout attempt at $29.24 resistance
Hims & Hers rises 1.63% on growth

Hims & Hers (HIMS) stock is trading at $28.61, rising 1.63% on the day. The shares are positioned above short-term averages but remain below longer-term reference points, reflecting a mixed technical setup.

HIMS price prediction
24H 3.13%
$24.75
48H 3.04%
$24.73
7D 5.29%
$25.27
1M -15.54%
$20.27
3M -36.54%
$15.23
6M -62.29%
$9.05
12M -44.33%
$13.36
Current price: $24 -1.9950 7.67%
Real-time Data 11:41
Daily range 23.78 Arrow from to Icon 25.67
Weekly range 22.95 Arrow from to Icon 28.61
Loading...

Highlights

  • Hims & Hers posted strong subscriber growth and further expanded branded weight loss offerings during the second quarter of 2026.
  • Increased customer acquisition and engagement stemmed from new AI-powered services and a more diversified product portfolio.
  • Shares of Hims & Hers trade in a range of $26.7 to $30.52 with mixed technical signals and defined resistance at $29.24.

Subscriber expansion and AI-driven engagement boost growth outlook

Hims & Hers delivered strong subscriber growth and increased adoption of its branded weight loss offerings in the second quarter of 2026, directly expanding its core user base and revenue streams. Management also reported significant gains in customer acquisition driven by adoption of new AI-powered services alongside a diversification of product categories, supporting the company’s growth outlook. According to Markets Financialcontent, the implementation of AI-native features in Hers weight loss drove notable engagement improvements, which are expected to yield ongoing benefits as these capabilities expand.

Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Oscillator divergence emerges as stock tests key resistance

Technically, HIMS is trading above its MA-20 at $28.6, while still below the MA-50 at $30 and the longer-term MA-200 at $29.17. The Ichimoku Kijun sits at $29.24 and marks immediate resistance. Momentum readings show both MACD and ADX indicating strong selling pressure. RSI is at 42.46 (Sell), CCI is Neutral, and the Stochastic RSI flags an Overbought condition. Bull/Bear Power demonstrates notable buyer dominance, highlighting divergence among oscillators.

Downside risk prevails unless breakout exceeds immediate resistance

In the short term, HIMS is likely to remain within a typical volatility band of $26.7 to $30.52. The upward scenario would require a break above resistance at $29.24, which could trigger further gains. Conversely, if support at $26.7 fails, a downside move is likely. The baseline scenario is for rangebound action near current price levels, with a 43% probability of an upward break and greater odds favoring a downward move.

Viktoras Karapetjanc, Traders Union expert, sees Hims & Hers maintaining strong fundamental momentum on the back of robust subscriber growth and successful expansion in branded weight loss offerings. He believes improved customer engagement from AI initiatives and product line diversification underpin solid long-term demand, despite current technical consolidation below key averages. Karapetjanc notes that while short-term indicators reveal oscillating sentiment, the business fundamentals remain a constructive force. "If HIMS can clear resistance at $29.24, I expect renewed bullish momentum built on its strong growth narrative," he says.

Earlier, analysts noted that Hims & Hers Health faced persistent headwinds and elevated downside risk, with technical signals pointing to ongoing pressure on the stock. The current setup reinforces this cautious outlook, as prevailing selling pressure and resistance at $29.24 highlight the importance of monitoring for a decisive break in either direction.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.